Business
CSL profits boom 45pc as flu business soars – The Australian Financial Review
The blood products giant notched up its fastest profit and revenue growth in recent years despite a uniquely challenging first half.
Sales of CSLs Hizentra product grew strongly, up 19 per cent, reflecting the benefits of home administration and the continued strong uptake for the treatment of the debilitating neurological disorder CIDP (chronic inflammatory demyelinating polyneuropathy).
The company declared a dividend of $US1.04 per share, up 9 per cent.
Guidance maintained
Despite the strong growth in the first half, the company maintained its full-year guidance of net profit of $US2.17 billion to $US2.265 billion at constant…
-
Noosa News21 hours agoTributes for woman allegedly mowed down on footpath in Maroochydore; Guilherme Dal Bo charged
-
General14 hours agoTwo people arrested after man fatally shot at McLaren Flat
-
General18 hours agoMan refused bail charged with depicting Adolf Hitler and Nazi symbols on boat
-
General7 hours agoThe one tweak that could grow your super by $200,000